supplementary tables.docx (17.22 kB)

supplementary tables: Real-world use and acceptance of biosimilar monoclonal antibodies of rituximab in oncology practice in the USA.docx

dataset

posted on 2021-07-14, 12:51 authored by Ahmed Shelbaya, John M Kelton, Jeffrey Thompson, Jose MJ Alvir, Martine C Maculaitis, Jingyan Yang

Supplementary Table 1. Definitions of Dosing and Treatment Patterns Variables

Supplementary Table 2. Treatment Utilization Patterns of Rituximab-pvvr in Patients with NHL and CLL

Real-World Use and Acceptance of Biosimilar Monoclonal Antibodies of Rituximab in Oncology Practice in the United States

Funding

Pfizer

History

Usage metrics

Future Oncology

Categories

Cancer therapy (excl. chemotherapy and radiation therapy)

Keywords

biosimilars chronic lymphocytic leukemia Monoclonal antibodies oncology rituximab-pvvr Non-Hodgkin’s lymphoma Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

Licence

CC BY-NC-ND 4.0

Exports